

I. Epidemiological profile

Population	2014	%
High transmission (>1 case per 1000 population)	93 500	4
Low transmission (0-1 cases per 1000 population)	1 380 000	62
Malaria free (0 cases)	748 000	34
Total	2 220 000	

Parasites and vectors

Major plasmodium species: *P. falciparum* (100%), *P. vivax* (0%)
 Major anopheles species: *An. arabiensis*, *An. gambiae*

Programme phase: Control

Reported confirmed cases: 1346 Estimated cases, 2013: [530-2100]
 Reported deaths: 22 Estimated deaths, 2013: <10

II. Intervention policies and strategies

Intervention	Policies/strategies	Yes/No	Adopted
ITN	ITNs/LLINs distributed free of charge	Yes	2009
	ITNs/LLINs distributed to all age groups	Yes	2009
IRS	IRS is recommended	Yes	1950
	DDT is authorized for IRS	Yes	-
Larval control	Use of larval control recommended	Yes	2012
IPT	IPT used to prevent malaria during pregnancy	-	-
Diagnosis	Patients of all ages should receive diagnostic test	Yes	2010
	Malaria diagnosis is free of charge in the public sector	Yes	1974
Treatment	ACT is free for all ages in public sector	Yes	2007
	Sale of oral artemisinin-based monotherapies	Never allowed	2007
	Single dose of primaquine is used as gametocidal medicine for <i>P. falciparum</i>	-	-
	Primaquine is used for radical treatment of <i>P. vivax</i>	-	-
	G6PD test is a requirement before treatment with primaquine	No	-
	Directly observed treatment with primaquine is undertaken	No	-
	System for monitoring of adverse reactions to antimalarials exists	Yes	-
Surveillance	ACD for case investigation (reactive)	Yes	2012
	ACD of febrile cases at community level (pro-active)	Yes	2012
	Mass screening is undertaken	-	2012
	Uncomplicated <i>P. falciparum</i> cases routinely admitted	No	-
	Uncomplicated <i>P. vivax</i> cases routinely admitted	No	-

Antimalaria treatment policy

Medicine	Adopted
First-line treatment of unconfirmed malaria	AL 2007
First-line treatment of <i>P. falciparum</i>	AL 2007
Treatment failure of <i>P. falciparum</i>	QN 2007
Treatment of severe malaria	QN 2007
Treatment of <i>P. vivax</i>	-
Dosage of primaquine for radical treatment of <i>P. vivax</i>	-
Type of RDT used	<i>P. f.</i> only.

Therapeutic efficacy tests (clinical and parasitological failure, %)


Medicine	Year	Min	Median	Max	Follow-up	No. of studies	Species
-	-	-	-	-	-	-	-

Insecticide susceptibility bioassays (reported resistance to at least one insecticide for any vector at any locality)

Year	Pyrethroid	DDT	Carbamate	Organophosphate	Species/complex tested
2010-2013	Yes	No	No	-	<i>An. gambiae</i> s.l.

III. Financing

Sources of financing




Financing by intervention in 2014


No data reported for 2014

IV. Coverage


ITN and IRS coverage




Cases tested and treated in public sector



Cases tracked




Test positivity




V. Impact

Confirmed malaria cases per 1000 and ABER



Malaria admissions and deaths



Impact: On track for >75% decrease in incidence 2000-2015